Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB08882_nanopub.RA6cv_ki6faPFuwS1BImJSSQn-7bVDACAoHKl4ti_Gj3A#assertion>. }
Showing items 1 to 20 of
20
with 100 items per page.
- drugbank:DB08882 type drugbank_vocabulary:Drug assertion.
- drugbank:DB08882 label "Linagliptin [drugbank:DB08882]" assertion.
- drugbank:DB08882 seeAlso DB08882 assertion.
- drugbank:DB08882 seeAlso linagliptin.html assertion.
- drugbank:DB08882 seeAlso tradjenta-drug.htm assertion.
- drugbank:DB08882 identifier "drugbank:DB08882" assertion.
- drugbank:DB08882 description "Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [Wikipedia]. Two pharmacological characteristics that sets linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. FDA approved on May 2, 2011." assertion.
- drugbank:DB08882 title "Linagliptin" assertion.
- drugbank:DB08882 bio2rdf_vocabulary:identifier "DB08882" assertion.
- drugbank:DB08882 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB08882 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB08882" assertion.
- drugbank:DB08882 bio2rdf_vocabulary:x-identifiers.org DB08882 assertion.
- drugbank:DB08882 drugbank_vocabulary:drugbank-id "DB08882" assertion.
- drugbank:DB08882 drugbank_vocabulary:x-cas cas:668270-12-0 assertion.
- drugbank:DB08882 drugbank_vocabulary:x-ahfs ahfs:68:20.05 assertion.
- drugbank:DB08882 drugbank_vocabulary:x-atc atc:A10BH05 assertion.
- drugbank:DB08882 drugbank_vocabulary:x-chebi chebi:68610 assertion.
- drugbank:DB08882 drugbank_vocabulary:x-kegg kegg:D09566 assertion.
- drugbank:DB08882 drugbank_vocabulary:x-wikipedia wikipedia:Linagliptin assertion.
- drugbank:DB08882 drugbank_vocabulary:x-ndc ndc:0597-0146-60 assertion.